NCT03011619

Brief Summary

Moderately to severely depressed subjects will be randomized to the "Control Group," who will receive care as usual, or the "CBT Group," who will receive care as usual in addition to the manualized course of Cognitive Behavioral Therapy (CBT).

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2017

Shorter than P25 for not_applicable depression

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 4, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 5, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

April 6, 2017

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 5, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 5, 2018

Completed
Last Updated

March 26, 2019

Status Verified

March 1, 2019

Enrollment Period

12 months

First QC Date

January 4, 2017

Last Update Submit

March 22, 2019

Conditions

Keywords

DepressionCognitive Behavioral Therapy (CBT)

Outcome Measures

Primary Outcomes (3)

  • Montgomery-Ashberg Depression Scale (MADRS)

    A ten-item clinician-administered questionnaire used to measure the severity of depressive symptoms in patients with mood disorders. The ten questions rate the severity of symptoms on scale of 0 (not present), 2 (mild), 4 (moderate), and 6 (severe). It is designed to be sensitive to change, so is often the scale of choice when interventions, such as psychotherapies, electroconvulsive therapy, or drug trials, are being studied.

    15 Minutes

  • Hamilton Rating Scale for Depression (HAM-D)

    Clinician-administered semi-structured interview with 17 questions. It is designed to measure the severity of depressive symptoms in patients with a primary depressive illness.

    20 Minutes

  • Clinical Global Impression Severity Scale (CGI-S)

    Single-item rating scale of the clinician's assessment of the global severity of depressive symptoms in relation to the clinician's total experience with depressed patients. Severity is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    20 Minutes

Study Arms (2)

Control Condition

ACTIVE COMPARATOR

usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.

Behavioral: Usual Standard of Care

CBT Condition

EXPERIMENTAL

If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.

Behavioral: Usual Standard of CareBehavioral: Cognitive Behavioral Therapy Condition (CBT)

Interventions

medication management, group therapy, and individual therapy.

CBT ConditionControl Condition

CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.

CBT Condition

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with depression according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria on initial assessment on the unit.
  • Demonstrates at least moderate degree of depressive symptoms on MADRS, HAM-D, and CGI-S.
  • Provides written informed consent.

You may not qualify if:

  • A mental illness other than depression that is the primary cause of treatment, as determined by the Principal Investigator.
  • A cognitive or neurologic disorder that inhibits ability to engage in CBT.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Jacqueline Sergie, MD

    NYU School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2017

First Posted

January 5, 2017

Study Start

April 6, 2017

Primary Completion

April 5, 2018

Study Completion

April 5, 2018

Last Updated

March 26, 2019

Record last verified: 2019-03

Locations